Back to GetFilings.com



Table of Contents

 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 

 
FORM 10-Q
 

 
 
x
 
Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934.  For the quarterly period ended June 30, 2002.
 
 
¨
 
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.  For the transition period from                      to                     .
 
Commission File Number
0-25133
 

 
PHARMANETICS, INC.
(Exact Name of Registrant as Specified in its Charter)
 

 
North Carolina
(State or other jurisdiction of
Incorporation or organization)
 
 
56-2098302
(IRS Employer
Identification Number)
 
9401 Globe Center Drive, Suite 140
Morrisville, North Carolina
(Address of Principal Executive Office)
 
27560
(Zip Code)
 
Registrant’s Telephone Number, Including Area Code 919-582-2600
 

 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES  x    NO  ¨
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 
Class

 
Outstanding as of August 6, 2002

Common Stock, no par value
 
9,570,638
 


Table of Contents
PHARMANETICS, INC.
 
INDEX TO FORM 10-Q
 
             
PAGE

PART I.
  
FINANCIAL INFORMATION
    
    
Item 1.
 
Financial Statements
    
           
3
           
4
           
5
           
6
    
Item 2.
    
8
PART II.
  
OTHER INFORMATION
    
    
Item 4.
    
12
  
13


Table of Contents
 
PHARMANETICS, INC.
 
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
 
    
JUNE 30,
2002

      
DECEMBER 31, 2001

 
    
(UNAUDITED)
          
ASSETS
                   
Current assets:
                   
Cash and cash equivalents
  
$
9,489
 
    
$
14,883
 
Accounts and other receivables
  
 
647
 
    
 
462
 
Inventories
  
 
2,288
 
    
 
2,223
 
Other current assets
  
 
389
 
    
 
242
 
    


    


Total current assets
  
 
12,813
 
    
 
17,810
 
Property and equipment, net
  
 
8,410
 
    
 
8,503
 
Patents and intellectual property, net
  
 
540
 
    
 
551
 
Other noncurrent assets
  
 
110
 
    
 
150
 
    


    


Total assets
  
$
21,873
 
    
$
27,014
 
    


    


LIABILITIES, REDEEMABLE PREFERRED STOCK, CONTINGENTLY REDEEMABLE COMMON STOCK AND SHAREHOLDERS’ EQUITY
                   
Current liabilities:
                   
Accounts payable
  
$
544
 
    
$
741
 
Accrued expenses
  
 
216
 
    
 
723
 
Deferred revenue, current portion
  
 
647
 
    
 
487
 
Current portion of long-term debt and capital lease obligations
  
 
24
 
    
 
23
 
    


    


Total current liabilities
  
 
1,431
 
    
 
1,974
 
Noncurrent liabilities:
                   
Deferred revenue, less current portion
  
 
1,101
 
    
 
1,346
 
Long-term debt and capital lease obligations, less current portion
  
 
55
 
    
 
66
 
    


    


Total noncurrent liabilities
  
 
1,156
 
    
 
1,412
 
    


    


Total liabilities
  
 
2,587
 
    
 
3,386
 
Series A convertible redeemable preferred stock, no par value; authorized 120,000 shares; 90,500 shares issued and outstanding at June 30, 2002 and December 31, 2001, respectively (aggregate liquidation value at June 30, 2002 of $9,050,000)
  
 
7,520
 
    
 
7,520
 
Contingently redeemable common stock
  
 
13,232
 
    
 
8,538
 
Shareholders’ equity:
                   
Common stock, no par value; authorized 40,000,000 shares; 9,577,738 and 9,485,294 issued and outstanding at June 30, 2002 and December 31, 2001, respectively
  
 
52,957
 
    
 
57,186
 
Accumulated deficit
  
 
(54,423
)
    
 
(49,616
)
    


    


Total shareholders’ equity
  
 
(1,466
)
    
 
7,570
 
    


    


Total liabilities, redeemable preferred stock, contingently redeemable common stock and shareholders’ equity
  
$
21,873
 
    
$
27,014
 
    


    


 
The accompanying notes are an integral part of the unaudited consolidated financial statements.

3


Table of Contents
PHARMANETICS, INC.
 
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
    
THREE MONTHS ENDED

    
SIX MONTHS ENDED

 
    
JUNE 30 2002

    
JUNE 30 2001

    
JUNE 30 2002

    
JUNE 30 2001

 
Net sales
  
$
798
 
  
$
1,322
 
  
$
1,741
 
  
$
2,124
 
Cost of goods sold
  
 
721
 
  
 
1,112
 
  
 
1,627
 
  
 
1,858
 
    


  


  


  


Gross profit
  
 
77
 
  
 
210
 
  
 
114
 
  
 
266
 
    


  


  


  


Operating expenses:
                                   
General and administrative
  
 
899
 
  
 
1,351
 
  
 
1,802
 
  
 
2,226
 
Sales and marketing
  
 
250
 
  
 
364
 
  
 
534
 
  
 
592
 
Research and development
  
 
1,402
 
  
 
931
 
  
 
2,663
 
  
 
1,750
 
    


  


  


  


Total operating expenses
  
 
2,551
 
  
 
2,646
 
  
 
4,999
 
  
 
4,568
 
    


  


  


  


Operating loss
  
 
(2,474
)
  
 
(2,436
)
  
 
(4,885
)
  
 
(4,302
)
    


  


  


  


Other income (expense):
                                   
Interest expense
  
 
(2
)
  
 
(40
)
  
 
(5
)
  
 
(67
)
Interest income
  
 
36
 
  
 
130
 
  
 
80
 
  
 
210
 
Grant/royalty income
  
 
25
 
  
 
12
 
  
 
25
 
  
 
12
 
Development income
  
 
114
 
  
 
50
 
  
 
228
 
  
 
100
 
Other expense
  
 
(22
)
  
 
(49
)
  
 
(21
)
  
 
(47
)
    


  


  


  


Total other income
  
 
151
 
  
 
103
 
  
 
307
 
  
 
208
 
    


  


  


  


Net and comprehensive loss
  
 
(2,323
)
  
 
(2,333
)
  
 
(4,578
)
  
 
(4,094
)
Dividends on preferred stock
  
 
103
 
  
 
144
 
  
 
228
 
  
 
291
 
    


  


  


  


Net loss applicable to common shareholders
  
($
2,426
)
  
($
2,477
)
  
($
4,806
)
  
($
4,385
)
    


  


  


  


Basic and diluted net loss per common share
  
($
0.25
)
  
($
0.28
)
  
($
0.50
)
  
($
0.53
)
    


  


  


  


Average weighted common shares outstanding
  
 
9,554,325
 
  
 
8,846,101
 
  
 
9,539,105
 
  
 
8,351,631
 
    


  


  


  


 
 
The accompanying notes are an integral part of the unaudited consolidated financial statements.

4


Table of Contents
PHARMANETICS, INC.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
    
Six Months Ended

 
    
June 30, 2002

    
June 30, 2001

 
Cash flows from operating activities:
                 
Net loss
  
($
4,578
)
  
($
4,094
)
Adjustments to reconcile net loss to net cash used in operating activities:
                 
(Gain) Loss on sale of assets
  
 
(1
)
  
 
49
 
Depreciation
  
 
748
 
  
 
555
 
Amortization of intangible and other assets
  
 
74
 
  
 
91
 
Amortization of discount on investments
  
 
—  
 
  
 
(31
)
Provision for inventory obsolescence
  
 
138
 
  
 
75
 
Change in operating assets and liabilities:
                 
Accounts receivable
  
 
(185
)
  
 
(586
)
Inventories
  
 
(203
)
  
 
(667
)
Other assets
  
 
(146
)
  
 
(121
)
Accounts payable and accrued expenses
  
 
(704
)
  
 
(514
)
Deferred revenue
  
 
(84
)
  
 
884
 
    


  


Net cash used in operating activities
  
 
(4,941
)
  
 
(4,359
)
    


  


Cash flows from investing activities:
                 
Payments for purchase of property and equipment
  
 
(662
)
  
 
(2,872
)
Disposal of property and equipment
  
 
7
 
  
 
—  
 
Costs incurred to obtain patents and intangibles
  
 
(24
)
  
 
(43
)
Purchases of investments
  
 
—  
 
  
 
(90